NVCN.TO - Neovasc Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.7700
-0.0800 (-9.41%)
As of 12:35PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.8500
Open0.8300
Bid0.7600 x 0
Ask0.7800 x 0
Day's Range0.7400 - 0.8800
52 Week Range0.5000 - 6.0000
Volume146,607
Avg. Volume189,179
Market Cap57.605M
Beta (3Y Monthly)4.68
PE Ratio (TTM)N/A
EPS (TTM)-2.5490
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.12
  • CNW Group23 hours ago

    Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

    VANCOUVER , June 25, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification (the "Nasdaq Notice") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum market value requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the "Listing Rules"). The Company received a letter from the Nasdaq in January 2019 notifying it that it was not in compliance with the minimum market value requirement set forth in Listing Rule 5550(b)(2).

  • CNW Group9 days ago

    Tiara™ Featured in Presentation at 11th Annual TVT 2019

    VANCOUVER , June 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a presentation at the 11th Annual Transcatheter Valve Therapy Conference ("TVT 2019"). In a presentation titled "The TIARA Program: Attributes, Challenges, and Early Clinical Data" Dr. Anson Cheung , Clinical Professor of Surgery and Director of Cardiac Transplant of British Columbia , and Principal Investigator for the Tiara Early Feasibility Study at St Paul's Hospital, Vancouver Canada , provided an update on the latest progress on the Tiara, including the challenging anatomical considerations,  patient characteristics,  procedural outcomes, and symptom improvement of patients treated with Tiara.

  • Benzinga15 days ago

    Penny Stock Neovasc Rallies On Patent Abstract Filing

    Shares of the Canadian medical device maker Neovasc Inc (NASDAQ: NVCN) were rallying Tuesday following the circulation of a document with a patent abstract it filed with the U.S. Patent and Trademark Office. The patent abstract pertains to the methods and apparatus for loading a prosthesis onto a delivery system. This relates to the company's Tiara prosthetic valve, which replaces the mitral valve of the heart when delivered through the apex of the heart.

  • PR Newswire19 days ago

    Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

    VANCOUVER, June 7, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that following 10 consecutive business days with a market value of listed securities ("MVLS") of over US$35 million, the Company has been advised by staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Nasdaq will exercise its discretion to continue to monitor the Company's MVLS pursuant to Nasdaq Listing Rule 5810(c)(3)(G) in connection with the Company's deficiency under the US$35 million minimum MVLS requirement. Nasdaq Listing Rule 5810(c)(3)(G) provides that Nasdaq staff may require satisfaction of the US$35 million minimum MVLS requirement for a period in excess of 10 consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

  • PR Newswire22 days ago

    Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders and Provides Update on Neovasc Reducer™

    VANCOUVER, June 4, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on June 4, 2019 in Vancouver, B.C. (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Dr. Jane Hsiao and Alexei Marko and elected Fred Colen to serve in office until the next annual meeting or until their successors are duly elected or appointed. At the Meeting, the Shareholders also approved resolutions authorizing the Company's Board of Directors to, at their discretion, execute a common share consolidation (72.43% of votes cast in favour) and re-appointing Grant Thornton LLP, Chartered Accountants as auditors of the Company.

  • PR Newswire29 days ago

    Neovasc Announces Publication of Peer-Reviewed Article in European Heart Journal Concluding Positive Cost-Effectiveness of the Neovasc Reducer™

    VANCOUVER, May 28, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the European Heart Journal, Quality of Care and Clinical Outcomes has published a peer-reviewed article indicating the cost effectiveness of the Neovasc Reducer™ ("Reducer") as an effective therapy for patients suffering from refractory angina, and its positive impact on healthcare burden.

  • PR Newswirelast month

    New Tiara and Reducer Data Presented in Several Presentations at the EuroPCR 2019 Conference in Paris

    VANCOUVER, May 23, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that new data for its Tiara™ ("Tiara") transcatheter mitral valve replacement device and Neovasc Reducer™ ("Reducer") device for the treatment of refractory angina were presented in several presentations at the EuroPCR 2019 Conference held this week in Paris, France.

  • Benzingalast month

    The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Axsome Therapeutics Inc (NASDAQ: AXSM ) Milestone Pharmaceuticals ...

  • PR Newswirelast month

    Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer™ in a Peer Reviewed Article in the International Journal of Cardiology

    VANCOUVER, May 22, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the International Journal of Cardiology has published a peer reviewed article regarding long term sustained efficacy and safety of the Reducer therapy in 50 patients suffering from refractory disabling angina. "This study shows us that the Reducer has a sustained therapeutic effect at two years across a large patient population. In addition, we believe this study provides valuable long-term safety data that further supports cardiologists use of the Reducer as a therapeutic option for patients suffering from refractory angina," commented Prof. Shmuel Banai, Medical Director of Neovasc.

  • PR Newswirelast month

    Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million

    VANCOUVER, May 16, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN) announced today that it has closed its previously announced private placement (the "Private Placement") of (i) a 15% original issue discount convertible debenture (the "Debenture") with a face value of US$11.5 million, for gross proceeds to the Company of US$9,775,000, and (ii) 3,349,514 common shares of the Company (the "Common Shares") at a price of US$0.515 per Common Share, for gross proceeds to the Company of US$1,725,000 (collectively, the "Offering"). The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the Toronto Stock Exchange will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq Capital Market.

  • PR Newswirelast month

    Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million

    VANCOUVER, May 14, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has entered into an agreement to sell to Strul Medical Group LLC ("SMG") (i) a 15% original issue discount convertible debenture (the "Debenture") with a face value of US$11.5 million, for gross proceeds to the Company of US$9,775,000, and (ii) 3,349,514 common shares of the Company ("Common Shares") at a price of US$0.515 per Common Share, for gross proceeds to the Company of US$1,725,000 (collectively, the "Offering").

  • Associated Press2 months ago

    Neovasc: 1Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had a loss of 21 cents per share. Losses, adjusted for asset impairment costs, came to 20 cents per share. The medical device company posted revenue ...

  • PR Newswire2 months ago

    /C O R R E C T I O N from Source -- Neovasc Inc./

    The news release, Neovasc Announces First Quarter 2019 Financial Results, published at 4:00 p.m. ET on May 9, 2019 inadvertently included a statement that the Company had announced a financing. While the Company is always considering ways to improve its capital position on terms that the Company believes are favorable, there can be no assurance that any financing will be completed.

  • CNW Group2 months ago

    Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

    This is especially true when these people suffer from refractory angina, which is angina that persists despite optimal drug therapy and revascularization. "We are pleased to have treated the 1,000th patient to receive the Reducer therapy at the Inselspital Universitätsspital Bern ". The Reducer therapy now totals medical evidence spanning 1,000 patients and 14 years of follow up.